EF Hutton initiated coverage of Artelo Biosciences with a Buy rating and $6 price target Artelo is an emerging biotechnology company focused on cachexia and chemotherapy-induced peripheral neuropathy, the analyst tells investors in a research note. The firm says the company is early in its growth phase, and raising capital will be mission-critical to realize the next series of value inflection points.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL: